摘要
目的 探讨HC5 6基因与化疗敏感性的关系。方法 把HC5 6基因转染Jurkat细胞 ,经G418筛选 ,获得稳定表达外源HC5 6基因的细胞克隆后 ,应用MTT法 ,观察HC5 6基因产物对Jurkat细胞拓扑异构酶Ⅱ抑制剂足叶乙甙 (etoposide ,VP16)敏感性的影响。结果 HC5 6基因转染Jurkat细胞 ,在 1μg ml、10 μg ml、5 0 μg ml浓度的VP16作用下 ,对细胞生长的相对抑制率分别为 5 1.7%± 4.2 % ,45 .1%± 3 .7% ,79.6%± 6.2 % ,明显高于在相应的VP16浓度作用下的PBK CMV空载体转染的对照细胞(分别为 9.5 %± 0 .6% ,7.0 %± 0 .5 % ,10 .2 %± 0 .9% ) (P <0 .0 1)。结论 HC 5
Objective To investigate the correlation between HC56 gene and chemotheraputic sensitivity.Methods HC56 gene was transfected into Jurkat cells,and the sensitivity to topoisomerase Ⅱ inhibitor etoposide(VP16) of Jurkat cells which stably express HC56 gene screened with G418,was investigated by MTT.Results The relative suppressive rate on viability of Jurkat cells transfected with HC56 gene exposure to 1 μg/ml,10 μg/ml and 50 μg/ml of etoposide was 51.7%±4.2%,45.1%±3.7%,79.6%±6.2% resepectively,it decreased significantly( P <0.01) as compared with control cells transfected with PBK/CMV vector exposure to the same concentration etoposide(9.5%±0.6%,7.0%±0.5%,10.2%±0.9% resepectively).Conclusion HC56 gene products could sensitize Jurkat cells to etoposide.
出处
《实用癌症杂志》
2002年第5期458-459,465,共3页
The Practical Journal of Cancer
基金
教育部重点科学基金(教技司[2 0 0 0 ] 1 56号 )
广东省卫生厅科研基金 (粤卫 [2 0 0 1 ] 1 65号 )资助